A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group, Jens D Lundgren, Birgit Grund, Christina E Barkauskas, Thomas L Holland, Robert L Gottlieb, Uriel Sandkovsky, Samuel M Brown, Kirk U Knowlton, Wesley H Self, D Clark Files, Mamta K Jain, Thomas Benfield, Michael E Bowdish, Bradley G Leshnower, Jason V Baker, Jens-Ulrik Jensen, Edward M Gardner, Adit A Ginde, Estelle S Harris, Isik S Johansen, Norman Markowitz, Michael A Matthay, Lars Østergaard, Christina C Chang, Victoria J Davey, Anna Goodman, Elizabeth S Higgs, Daniel D Murray, Thomas A Murray, Roger Paredes, Mahesh K B Parmar, Andrew N Phillips, Cavan Reilly, Shweta Sharma, Robin L Dewar, Marc Teitelbaum, Deborah Wentworth, Huyen Cao, Paul Klekotka, Abdel G Babiker, Annetine C Gelijns, Virginia L Kan, Mark N Polizzotto, B Taylor Thompson, H Clifford Lane, James D Neaton
Abstract
Background: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.
Methods: In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo. In addition, all the patients received high-quality supportive care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of 7000 mg) or placebo was administered as a single intravenous infusion over a 1-hour period. The primary outcome was a sustained recovery during a 90-day period, as assessed in a time-to-event analysis. An interim futility assessment was performed on the basis of a seven-category ordinal scale for pulmonary function on day 5.
Results: On October 26, 2020, the data and safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the LY-CoV555 group and 151 in the placebo group) had undergone randomization and infusion. The median interval since the onset of symptoms was 7 days (interquartile range, 5 to 9). At day 5, a total of 81 patients (50%) in the LY-CoV555 group and 81 (54%) in the placebo group were in one of the two most favorable categories of the pulmonary outcome. Across the seven categories, the odds ratio of being in a more favorable category in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.56 to 1.29; P = 0.45). The percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.56; 95% CI, 0.78 to 3.10; P = 0.20). The rate ratio for a sustained recovery was 1.06 (95% CI, 0.77 to 1.47).
Conclusions: Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure. (Funded by Operation Warp Speed and others; TICO ClinicalTrials.gov number, NCT04501978.).
Copyright © 2020 Massachusetts Medical Society.
Figures
References
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med 2020;383:1813-1826.
- The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2021436.
- Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2029849.
- National Institutes of Health. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). 2020. ().
- Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. October 9, 2020. (). preprint.
- Murray DD, Babiker AG, Baker JV, et al. Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: an Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative. November 13, 2020. (). preprint.
- World Health Organization. Novel coronavirus: COVID-19 therapeutic trial synopsis. 2020. ().
- Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events: corrected version 2.1, July 2017 ().
- McCullagh P. Regression models for ordinal data. J R Stat Soc B 1980;42:109-127.
- R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2020.
- Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020;369:1014-1018.
- Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. July 22, 2020. (). preprint.
- Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 2020;584:353-363.
- Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020;5:1185-1191.
- Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-2303.
Source: PubMed